The overall positive rates of mSEPT9 and CEA in the pre-operative blood samples of patients with confirmed CRC were 73.2% (95% CI, 65.0–81.1%) and 48.2% (95% CI, 38.1–57.3%; P < 0.001), respectively. The gene discussed is CEACAM5; the disease is colorectal carcinoma.